Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 438

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 438
---
 the human Interferon -betagene, has led to the development of Interferon -betatherapy for the treatment of multiple sclerosis, Rebif ®, a Blockbuster drug marketed worldwide which was later sold to Merck Serono. In recent years, Prof. Revel’s laboratory has focused on hESC and has succeeded in producing nerve myelinating cells that, when transplanted in myelin -deficientanimals, have regenerated the myelin coating. These studies contributed to the development of a suspension culture technology for hESC which can then be used to produce differentiated human cells such as insulin -producingpancreatic beta cells and nerve myelinating cells. Alongside his research and development activity, Prof. Revel is deeply involved in the ethics of science and biotechnology, and served as Chairman of the Israel National Bioethics Council and was a member of the International Bioethics Committee of UNESCO. Prof. Revel was the recipient of the Israel Prize for medical research, the EMET Prize for biotechnology, and is a member of the Israel Academy of Science and Humanities. He has been a member of Israel’s National Committee for Biotechnology, serving for three years as its Chairman. Professor Revel holds M.D. and Ph.D. degrees from the University of Strasbourg, France.

250 Kfir Molakandov PhD, Vice President Research and Development Dr. Kfir Molakandov has served as Vice President and Head of Research and Development at Kadimastem since January 2018, and he was previously a researcher at Kadimastem from January 2011 until December 2017. He received his B.A, M.Sc. in Cell and Gene Therapy for Diabetes and Ph.D. in Cell Therapy for Diabetes from Tel Aviv University, Israel. Uri Ben Or, Chief Financial Officer Mr.Uri BenOr has served as Kadimastem’s Chief Financial Officer since June 2022 and its controller since its inception in 2010. Uri Ben Or brings over twenty -fiveyears of broad experience in corporate finance, accounting, M&A transactions, and IPOs. He has significant expertise, including serving as chief executive officer, with public life science companies traded on the Nasdaq and TASE. Since June 2007, Uri has also served as the Chief Financial Officer of Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), and since September 2022, as the Chief Financial Officer of Wind -Buzz(TASE:WNBZ -L). From January 2021 to